Clinical Trials › NCT03477500
Active, Not RecruitingPhase 3
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)
Sponsored by Haukeland University Hospital
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 100
Target enrollment
Mar 2018
Start date
Mar 2028
Expected completion
Interventions / Treatments
Cyclophosphamide and ATGAlemtuzumabCladribine PillOcrelizumab
Conditions studied
Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.